文献速递脊柱关节炎

早期中轴型脊柱关节炎骨形成调节标志物的5年变化

Changes in bone formation regulator biomarkers in early axial spondyloarthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于法国DESIR前瞻性队列708例早期中轴型SpA患者,随访5年发现血清BMP-7和硬骨素水平显著升高,而DKK-1无显著变化;BMP-7升高与疾病活动度相关,且TNF抑制剂使用会减弱其升高程度。

要点

  • 早期axSpA患者5年内血清BMP-7中位相对变化达223.7%,与炎症活动相关。
  • 血清硬骨素中位相对变化为14.8%,但无明确决定因素。
  • TNF抑制剂使用与BMP-7升高幅度较低相关。

核心结论

  • 早期axSpA患者5年内血清BMP-7变化与炎症相关,活动性疾病中升高更明显,但TNF抑制剂使用会减弱其升高。
  • 血清硬骨素水平随时间显著升高,但升高程度低于BMP-7。

研究设计与样本

  • DESIR队列为法国多中心前瞻性研究,纳入708例早期(>3个月且<3年)炎性背痛疑似axSpA患者。
  • 在基线、2年和5年检测血清BMP-7、硬骨素和DKK-1水平,采用混合线性模型分析随时间变化。

主要发现

  • 血清BMP-7随时间显著升高,中位相对变化223.7%[IQR 0-10 700(0.17 pg/ml/月),P < 0.001]。
  • 血清硬骨素随时间显著升高,中位相对变化14.8%[IQR -7.9-41.4%(0.001 ng/ml/月),P < 0.001]。
  • 血清DKK-1随时间无显著变化。
  • 活动性疾病(ASDAS-CRP ≥1.3)中血清BMP-7随时间升高(P = 0.01),但TNF抑制剂使用使其升高幅度减小(P < 0.001)。
  • 未发现与血清硬骨素变化相关的决定因素。

临床怎么用

  • 在早期axSpA中监测BMP-7可能反映炎症驱动的骨形成活动,但需结合疾病活动度和TNF抑制剂使用解释。
  • 硬骨素随时间升高但幅度较小,其临床意义尚不明确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The hallmark of advanced axial SpA (axSpA) is spine ankylosis due to excessive ectopic bone formation. This prospective study aimed to describe the changes in serum levels of different regulators [sclerostin, dickkopf-1 (DKK-1)] and markers of bone formation [bone morphogenetic protein 7 (BMP-7)] over 5 years in early axSpA patients and to assess determinants of such changes. METHODS: The DEvenir des Spondyloarthropathies Indifférenciées Récentes cohort is a prospective, multicentre French study of 708 patients with early (>3 months-<3 years) inflammatory back pain suggestive of axSpA. Serum levels of BMP-7, sclerostin and DKK-1 were assessed at baseline and after 2 and 5 years. Changes in bone formation regulators over time were analysed using mixed linear models. RESULTS: Serum BMP-7 significantly increased over time, with a median relative change of 223.7% [interquartile range (IQR) 0-10 700 (0.17 pg/ml/month), P < 0.001]. Serum sclerostin significantly increased over time, with a median relative change of 14.8% [IQR -7.9-41.4% (0.001 ng/ml/month), P < 0.001]. Serum DKK-1 did not significantly change over time. Serum BMP-7 increased over time in active disease (Ankylosing Spondylitis Disease Activity Score with CRP ≥1.3, P = 0.01), but the increase was less pronounced with TNF inhibitor (TNFi) use (P < 0.001). No determinant was associated with serum sclerostin change. CONCLUSION: Serum BMP-7 change over 5 years was related with inflammation; it was increased in active disease, but the increase was low with TNFi use. Serum sclerostin levels significantly increased over time, but to a lesser degree than for serum BMP-7. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, NCT01648907.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Descamps E, Molto A, Borderie D, et al. Changes in bone formation regulator biomarkers in early axial spondyloarthritis. Rheumatology (Oxford). 2021. PMID: 32888036. doi:10.1093/rheumatology/keaa296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。